Inflammatory markers have been found at higher concentrations in women than men with bacterial meningitis. To investigate sex-based differences in the response to dexamethasone, we performed a post hoc analysis of a double-blind, randomised multicentre trial of dexamethasone (10 mg, 4 times daily for 4 days) vs placebo in adults with bacterial meningitis. The primary outcome measure was the Glasgow outcome scale score at 8 weeks and interaction tests were used to examine subgroup differences. Between June 1993 and December 2001, 301 patients (56% male) were randomly assigned to a treatment group: 157 received dexamethasone and 144 placebo. Although dexamethasone reduced the risk of unfavourable outcome to a greater extent in women (relative risk [RR] 0.42, 95% confidence interval [CI] 0.21-0.86, P = .02) than men (RR 0.79, 95% CI 0.41-1.51, P = .55), on interaction testing (ratio of RR women:men 0.53, 95% CI 0.20-1.39, P = .19) patient sex was not a significant modifier of the effect of dexamethasone. K E Y W O R D S corticosteroids, infectious diseases, inflammation, neurology
| INTRODUCTION
Bacterial meningitis is a serious and life-threatening disease, and, despite advances in prevention and treatment, 1 it remains a cause of substantial morbidity and mortality worldwide. 2 Experimental models have demonstrated that outcome in bacterial meningitis is related to the severity of subarachnoid inflammation, which is improved by administration of corticosteroids, particularly dexamethasone. [3] [4] [5] Since the publication of a large multicentre European randomised controlled trial which showed treatment with corticosteroids improves outcome in adults with community-acquired bacterial meningitis, 6 dexamethasone has become an established adjunctive treatment, with several meta-analyses and implementation studies supporting its use in high-income countries. [7] [8] [9] Patient sex influences a wide range of biological processes, including immune responses, which contribute to differences in the prevalence and pathogenesis of infectious, inflammatory and autoimmune diseases. [10] [11] [12] [13] In a nationwide prospective cohort study investigating sex-based differences in community-acquired bacterial meningitis, male sex was found to be independently associated with a poor prognosis, despite the fact that women had a more severe illness on admission. 14 Women in this cohort exhibited higher serum inflammatory markers and appeared to have superior benefit from treatment with corticosteroids, although no significant interaction between sex and dexamethasone was found. However, since the study took place following widespread implementation of dexamethasone use in the Netherlands, only a small portion of patients were untreated. In addition, as this was an observational study, treatment effects must be carefully interpreted.
We therefore analysed sex-based differences in outcome and treatment effect of adjunctive dexamethasone therapy using data from the European Dexamethasone in Adulthood Bacterial Meningitis trial. 6 
| METHODS
We performed a post hoc analysis of a prospective, randomised, double-blind, multicentre trial in Europe, the enrolment for which took place between June 1993 and December 2001. Details of the study design, procedures, treatment, outcome assessment and statistical analysis, as well as the full list of participating centres and investigators can be found elsewhere. 6 In brief, patients were eligible for the study if they were aged 17 years or older, had suspected meningitis in combination with cloudy cerebrospinal fluid (CSF), presence of bacteria in CSF Gram staining, or a CSF leucocyte count >10 9 /L. Exclusion criteria were as follows: a history of hypersensitivity to β-lactams or corticosteroids; pregnancy; presence of a cerebrospinal shunt; treatment with oral or parenteral antibiotics in the preceding 48 h; a history of active tuberculosis or fungal infection; a recent history of head trauma, neurosurgery, or peptic ulcer disease; and enrolment in another trial at the time of the study. The study was conducted in accordance to the principles contained in the Declaration of Helsinki and was approved by the Medical Ethics Committee of the Academic Medical Centre, Amsterdam, The Netherlands, and by the institutional review board of each participating hospital. 6 All patients or their legally authorised representatives gave written informed consent prior to enrolment.
Patients were randomly assigned to receive either dexamethasone (10 mg every 6 h intravenously for 4 days, before or with the first dose of antibiotics) or placebo. Investigators were blinded to treatment assignments, which were concealed except in the event of an emergency. Patients were initially treated with amoxicillin (2 g given intravenously every 4 h) for 7-10 days. Routine blood and CSF studies and cultures were performed prior to antibiotic treatment and initial regimen was maintained or changed according to aetiology and clinical response. The protocol was later amended to allow investigators to follow local guidelines for administering empirical antibiotic therapy. The primary outcome measure was the score on the Glasgow outcome scale at 8 weeks, with a score of 5 indicating a favourable outcome and score of 1-4 indicating an unfavourable outcome. 15 Analysis of outcomes was performed on an intention-to-treat basis with the use of a last observation-carried-forward procedure.
Continuous variables are expressed as median (interquartile range)
and were compared using the Mann-Whitney U test; the Fisher exact test was used to study categorical variables. Severity of illness was calculated based on available clinical and laboratory data using the Dutch meningitis risk score. 16 Treatment effect is expressed as relative risk (RR) for treated vs untreated patients (with an RR < 1.0 indicating a beneficial effect). Forest plots were used to display treatment effects across subgroups and were created using Review Manager (RevMan), version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). A test for interaction, as described by Altman and Bland, 17 was performed to determine whether effect sizes differed significantly between men and women, and adjustment for potentially confounding variables was performed using logistic regression analysis.
All statistical tests were 2-tailed, and analyses were performed using IBM SPSS Statistics for Windows, version 25.0 (Armonk, NY: IBM Corp.), with a P-value <.05 considered statistically significant.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY. 18
What is already known about this subject
• Outcome in bacterial meningitis is associated with subarachnoid inflammation, which is improved by treatment with corticosteroids.
• Dexamethasone is a proven adjunctive therapy for adults with community-acquired bacterial meningitis.
• Higher inflammatory markers have been found in female than in male patients with bacterial meningitis.
What this study adds
• Risk reduction with dexamethasone therapy appears to be more pronounced in women, but formal testing did not demonstrate a significant modification of the effect of dexamethasone by patient sex.
• Future drug trials should ideally be powered to detect anticipated interactions between patient sex and treatment.
| RESULTS
In total, 301 patients were included in the trial, 157 (52%) of whom were randomly assigned to receive dexamethasone. There were 89 (57%) male patients in the dexamethasone group and 80 (56%) in the placebo group. Baseline characteristics and clinical and laboratory admission findings of male and female patients included in the study can be found in Table 1 . Overall, there were no statistically significant differences between sexes regarding these features. However, within the placebo group, women were older than men (median 52 vs 41 years, P = .005). Furthermore, there was a difference in the age of female patients between the 2 treatment groups (median 52 years for women in the placebo vs 44 years for women in the dexamethasone group, P = .02). In pneumococcal meningitis (Figure 2) It is widely recognised that females exhibit more robust innate and adaptive immune responses to self and foreign antigens than males, 10, 21 which is thought to be due to hormonal, genetic and environmental influences. 10, 22 Inflammation appears to be a common underlying feature of many disorders that disproportionally affect women 23 and glucocorticoids are a cornerstone in the treatment of many inflammatory disorders. 24 Men and women can also differ in drug pharmacokinetics and pharmacodynamics, 25 and clinical efficacy of glucocorticoid treatment depends on these parameters. [26] [27] [28] [29] [30] [31] [32] Consequently, it is reasonable to expect there could be a sex-related difference in the effect of drug treatment, specifically that a stronger immune reaction might render women more responsive to antiinflammatory therapies.
The results of our analysis are consistent with previous observational findings, 14 improved, as has the overall outcome, 2,33-36 and therefore the possibility that subgroup analyses of older data may not accurately reflect differences between men and women in the current patient population is a potential limitation.
Moreover, post hoc analyses must always be carefully interpreted, as they are prone to finding false results. An imbalance of prognostic factors between subgroups, negating the benefit of randomisation, was also a matter of concern, as was the possibility selection bias. To control for selection bias, we compared the baseline characteristics of patients enrolled in this study with data from 345 men and 351 women included in a prospective nationwide cohort of adults with acute bacterial meningitis, collected between 1998 and 2002 37 ;
there were no significant differences between the 2 studies with respect to the Glasgow coma scale score on admission.
In conclusion, despite an apparently more pronounced risk reduction in women than in men, we did not find the effect of adjunctive dexamethasone treatment to be significantly modified by patient sex.
Although these results do not support a change in treatment practices, they provide insight into sex-based differences in the response to anti-inflammatory therapy in bacterial meningitis; in addition, they should influence the design of future drug trials, which should take patient sex into account and, whenever possible, be adequately powered to detect anticipated treatment-subgroup interactions. Further research into the pathogenesis of sex-based differences in inflammatory reaction in bacterial meningitis, including the role of sex steroid hormones, is needed.
